{
  "pmcid": "8495602",
  "sha256": "2144ba3d1b73a4080913c167763b248803a8650c8c0f588e5b734d5da2dc4c76",
  "timestamp_utc": "2025-11-10T00:09:33.712476+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.51167091836735,
    "reading_ease": 18.29444515306122,
    "word_count": 245
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "A Randomised Controlled Trial of Primary Tumor Resection in Metastatic Colorectal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients with histologically confirmed mCRC, unresectable metastases, and minimal symptoms were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with histologically confirmed mCRC, unresectable metastases, and minimal symptoms"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either systemic treatment only or PTR followed by systemic treatment"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the impact of PTR on 60-day mortality."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was 60-day mortality."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between August 2012 and December 2019, 196 patients were randomised, with 98 assigned to each group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "In the intention-to-treat analysis, 60-day mortality was 3% (95% CI, 1%-9%) in the systemic treatment group and 11% (95% CI, 6%-19%) in the PTR group"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "60-day mortality was 3% (95% CI, 1%-9%) in the systemic treatment group and 11% (95% CI, 6%-19%) in the PTR group (P = .03)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Patients with elevated serum levels of lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, and/or neutrophils had significantly higher mortality in the PTR group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT01606098"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}